PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
PUMA BIOTECHNOLOGY, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $207.30M | $202.93M | $204.07M | $198.57M | $202.80M | $198.01M | $195.19M | $193.98M | $189.44M | $196.59M | $203.11M | $203.64M | 89.6% | +2.2% |
| Royalty [Member] | $23.94M | $24.25M | $24.30M | $13.43M | $35.26M | $34.70M | $35.28M | $49.59M | $29.71M | $30.04M | $32.53M | $25.49M | 10.4% | -32.1% |
By region
From the segment and revenue-disaggregation notes of Puma Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.